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SUMMARY
Aims: We evaluate safety and efficacy of autologous bone marrow-derived mesenchymal
stem cells (MSCs) as a potential treatment for neuromyelitis optica spectrum disorder
(NMOSD). Methods: Fifteen patients with NMOSD were recruited. All patients received a
single intravenous infusion of 1.0 9 108 autologous MSC within 3–4 generations derived
from bone marrow. The primary endpoints of the study were efficacy as reflected by reduc-
tion in annualized relapse rates (ARRs) and inflammatory lesions observed by MRI.
Results: At 12 months after MSC infusion, the mean ARR was reduced (1.1 vs. 0.3,
P = 0.002), and the T2 or gadolinium-enhancing T1 lesions decreased in the optic nerve
and spinal cord. Disability in these patients was reduced (EDSS, 4.3 vs. 4.9, P = 0.021; visual
acuity, 0.4 vs. 0.5, P = 0.007). The patients had an increase in retinal nerve fiber layer
thickness, optic nerve diameters and upper cervical cord area. We did not identify any seri-
ous MSC-related adverse events. At 24 months of MSC infusion, of 15 patients, 13 patients
(87%) remained relapse-free, the mean ARR decreased to 0.1; the disability of 6 patients
(40%) was improved, and the mean EDSS decreased to 4.0. Conclusions: This pilot trial
demonstrates that MSC infusion is safe, reduces the relapse frequency, and mitigates neuro-
logical disability with neural structures in the optic nerve and spinal cord recover in patients
with NMOSD. The beneficial effect of MSC infusion on NMOSD was maintained, at least to
some degree, throughout a 2-year observational period.
Introduction
Neuromyelitis optica (NMO), and its spectrum disorders, are
severe inflammatory central nervous system (CNS) disorders that
clinically manifests with attacks of optic neuritis and (or) myelitis.
Neuromyelitis optica spectrum disorders (NMOSDs) are character-
ized by autoantibodies against aquaporin 4 (AQP4) and perhaps
other neuronal antigens that activate the classical complement
cascade, which elicits inflammatory responses with marked gran-
ulocyte and macrophage infiltration. In turn, these inflammatory
responses cause secondary oligodendrocyte damage, demyelina-
tion, as well as poor remyelination and disease recovery [1,2].
Within active NMOSD lesions, both antibody- and cell-mediated
immunopathology can be visualized [1–3], suggesting diverse
immune effector mechanisms. Damage to the optic nerve and
spinal cord are usually prominent, especially during the early
stage of the disease. As a result of accumulating damage during
acute attacks, NMOSD runs a fast course by progressing to a partial
or complete loss of vision, and paraplegia around 5 years after
disease onset in the vast majority of these patients [4,5].
Halting damage accumulation in NMOSD poses significant
challenges. Some effective MS therapies, such as interferons,
natalizumab, and fingolimod, are not effective in NMOSD and,
in some individuals, even exacerbate disease [6–8]. Case stud-
ies and pilot trials have suggested that B-cell depletion with
rituximab, or complement inhibition with eculizumab, are
promising treatment strategies [9,10]. For complex diseases
such as NMOSD, immune-mediated tissue damage is orches-
trated by multiple cell types and cytokines. Targeting multiple
aspects of the pathogenic mechanisms may mitigate immune
damage and promote endogenous and exogenous repair mech-
anisms [11].
Bone marrow-derived mesenchymal stem cells (MSCs) are
adult stromal progenitor cells of mesodermal origin. MSC can
ª 2016 John Wiley & Sons Ltd CNS Neuroscience & Therapeutics 22 (2016) 677–685 677
differentiate into other cell types, which makes them attractive for
cell replacement therapy. Additionally, these cells also exert para-
crine effects by modulating the plasticity of damaged host tissues,
secreting neurotrophic and survival-promoting growth factors,
restoring synaptic transmitter release, integrating into existing
neural and synaptic networks, and re-establishing functional
afferent and efferent connections [12,13]. Moreover, MSCs pos-
sess strong immunomodulatory properties that inhibit the release
of pro-inflammatory cytokines from both innate and adaptive
immune cells [14,15]. These potent properties of MSC have been
tested in preclinical and clinical studies of several inflammatory
and autoimmune diseases [16–18]. The effects of intravenous
autologous MSC have been investigated in pilot trials with MS
patients [19–21]. Of particular relevance to the present work is
that MSC markedly improved visual impairments in some patients
with secondary progressive MS [22]. The potential dual effect of
MSC on tissue repair and modulation of immune functions
prompted us to initiate the current study on NMOSD.
Materials and Methods
Standard Protocol Approvals, Registrations, and
Patient Consents
The study protocol and informed consent procedures were
approved by the institutional review board at Tianjin Medical
University General Hospital. This study is registered with
ClinicalTrials.gov, number: NCT02249676.
Study Participants
Between September 2013 and January 2015, participants were
consecutively recruited into an open-label trial at Tianjin Medical
University General Hospital, Tianjin, China. Inclusion criteria
were as follows: clinically definite NMO, as defined by 2006 crite-
ria [23], or NMOSD with positive AQP4 antibody [either recurrent
optic neuritis (rON) or recurrent longitudinally extensive trans-
verse myelitis (rLETM) [24], being in remission period; expanded
disability status scale (EDSS) score ≥2.5; and age ranged from 16
to 65 years. Exclusion criteria included pregnancy, breastfeeding,
or plans to conceive during the course of the study (women only);
history of splenectomy or asplenia (potential increased risk of
meningococcal infection); and combined blood disorders, cancer,
active or chronic infection within at least 3 months. Written
informed consent was provided by the patients.
Procedures
Generation of Autologous MSC and Infusion
Production of autologous MSC is illustrated in Figure 1A. The phe-
notype of the cells was assessed by flow cytometry to confirm the
expression of CD73, CD90, and CD105 surface molecules (>95%)
and the absence of CD34, CD45, CD14, and CD3 (<2%), and the
ability of the cells to differentiate into adipocytes and osteocytes in
culture was confirmed in vitro following the 2006 International
Society of Cellular Therapy’s criteria [25]. Viability was greater
than 95% for infusion and tested negative for endotoxin, hepatitis
C virus, hepatitis B virus, HIV, syphilis, fungi, Mycoplasma spe-
cies, and chromosomal aberrations in the final cellular product
[26]. Confluent autologous MSCs at passages 3– 4 were collected
in M199 culture media containing 1% human serum albumin and
stored for up to 1 h at 4°C. MSC suspensions of 5 9 105/mL were
transferred into 200-mL syringes for intravenous infusion over
45 min. Each participant received single infusion of autologous
MSC administered intravenously at a dose of 1 9 108 cells which
had been used and shown efficacy for patients with primary pro-
gressive multiple sclerosis [20]. To reduce type I hypersensitivity
reactions, premedication with 10 mg chlorpheniramine, 100 mg
hydrocortisone, and 10 mg metoclopramide was given 30 min
before administration of the cells. After administration of cell sus-
pensions, we infused normal saline (500 mL) over 4 h. Partici-
pants were monitored clinically for evidence of adverse reactions
over a minimum of 24 h.
Follow-up
Participants were assessed at 1 day before treatment as baseline,
and at 1, 3, 6, 9, and 12 months after treatment (Figure 1A).
Assessment at each time point was within an interval of less than
1 week. Assessments included three parts: functional outcomes
[Expanded Disability Status Scale (EDSS), visual acuity, visual
field, visual evoked potential, and Paced Auditory Serial Addition
Test (PASAT)], structural outcomes [optic nerve, brain and spinal
cord MRs, and optical coherence tomography (OCT)], and poten-
tial information on the mechanism (serum AQP4 antibody and
immune phenotyping). Details of these assessments are described
in the Data S1. Relapses were defined as new or recurrent neuro-
logical symptoms not associated with fever or infection, lasting at
least 24 h, accompanied by new objective neurological findings
and separated from the onset of other confirmed relapses by at
least 30 days.
Safety was determined by immediate or delayed adverse events.
Immediate reactions included allergic reactions (tachycardia,
fever), respiratory failure, local complications (dizziness, lumbago,
headache), and systemic complications (systemic infections).
Delayed reactions included tumor formation.
During the second year after MSC infusion, only clinical out-
comes were assessed at each visit. Participants underwent clinical
ophthalmology, neurological function evaluations every
6 months.
Outcomes
The primary outcomes measure was efficacy as reflected by reduc-
tion in annual relapse rate and the number or volume of T2 and
enhancing lesions over 12 months after MSC treatment. The sec-
ondary outcome was efficacy for accelerating recovery included
neural function improvement (e.g., EDSS and visual acuity) and
tissue restoration (e.g., retinal nerve fiber layer thickness, optic
nerve area diameter, brain atrophy, and upper cervical cord area).
The third outcome was safety and feasibility. The images analysis
was performed by someone blinded to patient and sequence of the
studies.
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Statistical Analysis
Descriptive summaries are reported as means  SE for continuous
variables, mean (SD, range) for abnormal distribution variables
and as frequencies (%) for categorical variables. Paired compar-
isons of continuous outcomes of interest before and after treat-
ment were performed with paired t-test, discontinuous outcomes
or abnormal distribution with Wilcoxon signed rank test and cate-
gorical variables with chi-squared test. All tests were two-sided,
and P values of less than 0.05 were considered to be significant.
SPSS for Windows version 17.0 software (SPSS, Inc, Chicago, IL,
USA) was used for the analysis.
Results
Study Subject Characterization
We enrolled 15 patients (NMO: rON: rLETM, 12: 1:2) with a
mean age of 47 years and all patients completed follow-up and
data collecting. Baseline characteristics for patients are shown in
Table 1. The mean disease duration of patients was 9 years, and
13 of the 15 patients (87%) were positive for AQP4 antibodies.
In the 1–34 years before recruitment, 13 patients (25 eyes) had
clinical optic neuritis and 14 patients had longitudinally exten-
sive spinal cord lesions (≥3 vertebral segments) (Table S1).
Seven patients received prednisolone for preventing relapses
before MSC treatment, 6 patients received azathioprine or aza-
thioprine plus prednisolone, and 3 patients received cyclophos-
phamide treatment (Table 1). All patients failed previous
treatment (≥1 attack when receiving treatment) despite treat-
ment for over 90 days of duration.
Safety
We successfully isolated and cultured MSC to the target dose from
the bone marrow aspirates of all patients (1.0 9 108 cells per
patient). Mean culture duration was 25 days (20–30 days). We
did not record any adverse events during infusion. Only one
patient developed a low-grade fever (37.5°C) and knee pain at
about 3 h after the start of infusion that resolved spontaneously
over 2 h. Results of weekly blood testing of clinical chemistry and
hematology during the 4 weeks after infusion were unremark-
able. We did not identify tumor formation during the follow-up
phase.
Effects of MSC Infusion on Reducing Annual
Relapse Rate and Inflammatory Activity
Twelve patients remained completely relapse-free, and three
patients (20%) had at least 1 relapse, with a total of 4 mild
relapses among them after 12 months of MSC therapy. There was
no further worsening of EDSS scores during these relapses and the
new CNS symptoms and signs completely disappeared after
1 month. Among the relapses, 2 occurred within 1 month after
treatment. The mean annualized relapse rates before treatment
were 1.1 [0.9; 0.3–4.0 (SD, range)], whereas the mean annualized
relapse rates after MSC therapy were 0.3 [0.6; 0–2.0 (SD, range)].
The mean annualized relapse rates in the 12 months before initi-
ating BMSC therapy were 1.3 (a total of 19 relapse), and after
12 months of BMSC therapy, these decreased to 0.3, a reduction
of 76.9% (Figure 1B).
As shown in Figure 2, after receiving an MSC infusion, patients
had a reduced mean cumulative number of optic nerve and spinal
cord lesions on T2 images or gadolinium-enhancing T1 lesions at
12 months relative to baseline (0.2 vs. 0, P = 0.031; 0.13 vs. 0,
P = 0.043, respectively, for optic nerve, and 10 vs. 7 segments,
P < 0.001; 0.6 vs. 0.1, P = 0.015, respectively, for spinal cord).
Although the number of T2 lesions in the brain was not signifi-
cantly decreased (Figure 2G), the volume of T2 lesions in the
brain was reduced (2.6 vs. 1.8 mL, P = 0.035) (Figure 2H). There
were no gadolinium-enhancing lesions observed in the brain at
baseline and during the follow-up period.
Evidence of Disease Recovery
We observed a reduction after treatment in general disability
measured by EDSS (4.9 vs. 4.3, P = 0.021), which was promi-
nently reflected in pyramidal and sensory function, although we
did not identify a change in bowel or bladder function (Fig-
ure 3A–D). The EDSS scores were improved in 7 (47%) patients
and were stabilized in 8 patients, with an average 0.6 EDSS
score decrease at 12 months after MSC treatment. In contrast,
EDSS scores worsened in 9 patients, were stable in 4 patients,
and mildly improved in 2 patients (P < 0. 001), with an average
0.4 EDSS score increase (P = 0.002) during the 12-month period
before MSC treatment. After treatment, there was an improve-
ment in visual acuity (0.4 vs. 0.5, P = 0.007) (Figure 3E). No
significant changes were evident in visual fields (Figure 3F) and
visual evoked response latency. We also identified an improve-
ment in cognition as measured by PASAT (42 vs. 46,
P = 0.003).
Because acute swelling temporarily increases the tissue vol-
ume during disease relapses, patients with acute ON or myelitis
at 3 months before baseline assessment or during the follow-up
period were excluded. Imaging measures showed an increase in
retinal nerve fiber layer thickness from baseline to 12 months
Table 1 Baseline characteristics of patients
Number of participants 15
Sex ratio (men: women) 1:14
Age at enrollment (years) 47 (14; 19–63)
Age at disease onset 38 (15; 15–58)
Duration of disease (years) 9 (10; 1–34)
Diagnosis
Neuromyelitis optica 12
Relapsing optic neuritis 1
Relapsing transverse myelitis 2
Aquaporin 4 antibody positivity 13
Coexisting autoimmune diseases
Connective tissue disease 2
Hypothyroidism 1
Acute inflammatory demyelinating polyneuropathy 1
Annualized relapse rates 1.1 (0.9; 0.3–4.0)
Expanded disability status scale score 4.9 (2.1; 2.5–8.5)
Data are n or mean (SD; range).
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(73 vs. 81 lm, P < 0.001), optic nerve diameter (2.3 vs.
2.6 mm, P < 0.001), and upper cervical cord area (69 vs.
73 mm2, P < 0.001) after MSC treatment (Figure 4). No
changes were evident in macular volume, total cerebral volume,
cerebral gray matter volume and cerebral white volume after
treatment.
Impact of MSC Infusion on Lymphocyte
Subpopulations and Serum AQP4 Antibody
Concentrations
Immunological analyses indicated a decrease in CD19+ B-cell
counts and T follicular helper (Tfh)-cell counts at 1 month after
treatment, and at 3 months CD19+ B-cell and Tfh-cell counts
returned to baseline levels. Compared with baseline, no signifi-
cant changes were observed during the follow-up period in CD4,
Th1, Th17, Treg, natural killer (NK), and natural killer T (NKT)-
cell counts (Figure S1A-C).
Compared with baseline levels, fluctuations of anti-AQP4 anti-
body titers were observed starting 1 month after MSC treatment.
A decrease at 3 months (40 vs. 54 FU, P = 0.035) was evident,
but levels returned close to baseline at 6–12 months (Figure
S1D). Interestingly, the serum levels of IL-21 and IL-6 were also
decreased after 3 months of MSC treatment (Figure S1E,F).
The Second-Year Follow-Up of NMOSD Patients
in Annualized Relapse Rate and Disability after
MSC Infusion
Of the 15 patients, 13 showed (87%) remained relapse-free during
the second year after MSC infusion. The mean ARR was 1.1 (0.9)
before treatment, and the mean (SD) ARR at second year was 0.1
(0.3) (P < 0.001) after treatment. Among all patients, the EDSS
scores improved in 6 patients and stabilized in 9 during the second
year after MSC treatment. The mean EDSS score was 4.9 (SD, 2.1)
before MSC treatment and 4.0 (SD, 2.3) after treatment
(P < 0.001). So, a follow-up analysis during the second year of
this study revealed significant improvements in relapse rates and
disability which suggests that the effect of MSC therapy can last
more than 1 year (Table 2).
Figure 1 Study design and effects of MSC infusion on relapse of NMOSD. (A) Study design: Fifteen eligible patients with NMOSD were enrolled. Prior to
bone marrow aspiration, all treatments with corticosteroids and other systemic immunosuppression therapies were discontinued for 30 days. Bone
marrow cell aspirates (20 mL) were obtained while patients were under local anesthesia from the posterior iliac crest. Following current good
manufacturing practices, mononuclear bone marrow cells were isolated by Percoll (1.073 g/mL) centrifugation and allowed to adhere to a flask for 72 h in
low-glucose Dulbecco’s modified Eagle’s medium (GibcoInvitrogen), and the culture medium was changed every 3 days. The phenotype of the cells was
assessed by flow cytometry to confirm the expression of CD73, CD90, and CD105 surface molecules (>95%) and absence of CD34, CD45, CD14, and CD3
(<2%), and the ability of the cells to differentiate into adipocytes and osteocytes in culture was confirmed in vitro following the 2006 International Society
of Cellular Therapy’s criteria.25 At 70–80% confluence, cells were detached and re-plated at 1 9 106/175 cm2 culture to process for infusion. Cell viability
was determined by trypan blue staining at the end of the harvest. Viability was greater than 95% for infusion and tested negative for endotoxin, hepatitis C
virus, hepatitis B virus, HIV, syphilis, fungi, Mycoplasma species, and Chlamydia before infusion. G-banding karyotype analysis was performed to confirm
the absence of chromosomal aberrations in the final cellular product.26 After MSCs were characterized in accordance with the International Society of
Cellular Therapy (ISCT) recommendations,25 108 MSC of 5 9 105 cells/mL were transferred into 200-mL syringes for intravenous infusion over a 45-minute
time period for each patient. All participants were assessed at 1 day (D-1, baseline) before treatment and at 1 month (M + 1), 3 months (M + 3),
6 months (M + 6), 9 months (M + 9), and 12 months (M + 12) after treatment. Assessments included clinical assessment (Expanded Disability Status
Scale (EDSS) and Paced Auditory Serial Addition Test [PASAT]); optical nerve, brain, and spinal cord MRI; visual evoked potential, optical coherence
tomography (OCT), and ophthalmological assessments (visual acuity, visual field); serum anti-AQP4 antibody concentrations; and lymphocyte
phenotyping. (B) Frequency of relapses before and after mesenchymal stem cell (MSC) infusion, TM = transverse myelitis, ON = optic neuritis.
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(A)
(E)
(I)
(B)
(C) (D)
(G)
(K) (L)
(H)
(F)
(J)
Figure 2 Impact of MSC infusion on inflammatory activity in the optical nerve, brain and spinal cord. Optical nerve active lesions (red arrow) were
monitored on fat-suppressed T2 (A) and gadolinium-enhancing T1 sequences (B); MSC infusion reduced the number of T2 (C) and gadolinium-enhancing
lesions (D) in the optic nerve. Brain active lesions (red arrow) were measured on fluid-attenuated inversion recovery (FLAIR) (E) and gadolinium-enhancing
T1 sequences (F); patients had unchanged numbers of T2 brain lesions (G) but decreased volume of T2 brain lesions after MSC treatment (H). No
hyperintense signals appeared on gadolinium-enhancing T1 imaging between the baseline and follow-up period. Spinal cord active lesions (red arrows)
were assessed on T2 (I) and gadolinium-enhancing T1 (J) sequences. MSC reduced the number of segments of T2 lesions (K) and the number of
gadolinium-enhancing lesions in the spinal cord (L). All statistical analyses were performed by Wilcoxon signed rank test.
Figure 3 Assessment of visual and cognition functions in MSC-treated NMOSD patients. Paired changes in EDSS and functional systems scores (A–D,
n = 15 patients), visual acuity (E, n = 30 eyes), whole-field visual (F, n = 26 eyes; 4 eyes were excluded for inadequate quality for analysis), evoked
response latency (G, n = 26; 4 eyes were excluded for inadequate quality for analysis), and PASAT (H) are shown for individual patients at baseline and at
12 months after MSC treatment (solid lines). The mean changes are also shown (red dashed line). Statistical analyses were performed by Wilcoxon signed
rank test. PASAT, the Paced Auditory Serial Addition Task, was used to evaluate auditory processing speed, attention, and working memory.
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Discussion
Challenges to the management of patients with NMOSD are
related to its rapid disease progression and the limited efficacy of
disease-modifying drugs employed for MS. Development of thera-
pies for NMOSD is impeded by the lack of sensitive and specific
clinical assessment modalities designed specifically for NMOSD.
Further, the low incidence of NMOSD particularly among Cau-
casians and wide variations in the rate of disease progression
between individuals complicate clinical studies on NMOSD. In an
attempt to overcome these hurdles, we and several previous stud-
ies focused on a sentinel lesion that included the retrobulbar opti-
cal nerve and the upper cervical cord and retina, which has little
variability in patients and is sensitive to examination of clinical
(A)
(B)
(D)
(F)
(C)
(E)
Figure 4 Evidence of disease recovery in MSC-treated NMOSD patients. Color-scale raw optical coherence tomography scan (OCT) in the papillary area
(A, left) and pseudocolor thickness map generated from cube scan based on the thickness of the layers evaluated (A, right). Pseudocolor thickness map
images of an eye with history of optic neuritis showed that the retinal nerve fiber layer in the nasal inferior and temporal quadrants exhibited severe
thinness at baseline, whereas at 12 months after MSC treatment, the retinal nerve fiber layer in these areas had increased thickness. Compared with
baseline, the retinal nerve fiber layer thickness significantly increased at 12 months (B). Statistical analysis was performed with paired t-test, with n = 23
eyes (6 eyes were excluded due to optical neuritis relapse within the 12-month follow-up period, and one eye was excluded for inadequate signal strength
on OCT scan), including 18 eyes with a history of optical neuritis and 5 eyes without a history of optical neuritis. The axial fat-suppressed T2 sequence (C,
left) was used to measure optic nerve diameter in an axis perpendicular to the optic nerve 3 mm (C, right). The optic nerve was severely atrophied and
the optic nerve sheath appeared as a high signal surrounding a region of low signal corresponding to atrophy of the optic nerve at baseline. At 12 months
after MSC treatment, optic nerve atrophy improved and the high signal of the optic nerve sheath mostly disappeared. Compared with baseline, the optic
nerve diameter had significantly widened at 12 months after treatment (D). Statistical analysis was performed with paired t-test, with n = 24 eyes (6 eyes
were excluded due to optical neuritis relapse during the follow-up phase), including 19 eyes with a history of optical neuritis and 5 eyes without a history
of optical neuritis. Three-D T1 images showing mid-sagittal images of a NMO patient (E, right). White lines show the location of the upper cervical cord
assessment. Reformatted axial slices at cervical level C2 (E, left). Note the marked reduction in the upper cervical area at baseline. At 12 months after
MSC treatment, upper cervical cord atrophy had improved. Compared with baseline, the upper cervical cord area was significantly enlarged at 12 months
after treatment (F). Statistical analysis was performed with paired t-test, with n = 13 (one patient was excluded due to myelitis relapse during the follow-
up phase, and another patient was excluded for inadequate signal strength on MRI scans).
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outcomes [27–29]. With these approaches, we found that a single
infusion of autologous MSC slows the progression, or stabilizes or
improves neurological functions in patients with NMOSD over
1 year. These patients did not respond to previous treatment with
cyclophosphamide or azathioprine with or without prednisone for
reducing relapses. After receiving MSC, 12 of 15 patients were
completely free from relapses during the 12-month observation
period. Three patients together developed 4 mild relapses without
a decrease in EDSS. The new CNS symptoms and signs in the latter
patients completely recovered 1 month after the relapse. In accor-
dance with these clinical observations, MRI studies revealed
reduction in spinal cord and optic lesions. None of the 15 patients
reported severe adverse events during the 12-month follow-up
period. Therefore, these preliminary results provide evidence that
autologous MSC infusion is a safe and effective treatment for
NMOSD.
Without adequate tools to follow the infused MSC in vivo in
human and lack of in situ and pathological data, we do not know
precisely how and at what level MSCs modulate disease activity.
Whether replacement of injured cells by MSCs differentiated
locally contributes to the recovery is not clear. Although MSC
therapies were originally based on the possibility to restore the
damaged tissues, MSCs have emerged as a potential therapy for an
inflammatory demyelinating disease of the CNS based on other
properties than tissue replacement, such as their ability to inhibit
pathogenic T- and B-cell responses and on the release of neuro-
protective favoring tissue protection and repair [13–16]. Our study
suggests that alterations in inflammatory and autoimmune
responses occurred in the periphery and within the brain. In the
circulation, we followed counts of most lymphocytes and, among
them, only numbers of B cells were reduced upon MSC infusion.
Although anti-AQP4 antibody titers fluctuated during the follow-
up period, it is likely that alterations in antibody levels do not nec-
essarily reflect changes in overall B-cell numbers or subsets, as is
also the case for rituximab therapy [30]. Production of antibodies
against AQP4 is dependent on T helper cell [3]. Among several T
helper cell subsets analyzed, we found that Tfh cells were reduced
accompanied by reduction in IL-6 and IL-21. Tfh cells and cytoki-
nes of IL-21 and IL-6 support B-cell activation, expansion, and dif-
ferentiation and play a role in the generation of anti-AQP4
antibodies [31]. Our data suggested that MSC transplantation
might exert neuroprotection on NMOSD at least in part through
immune modulation of Tfh cells and cytokines of IL-6 and IL-21.
The mechanisms of action for MSC require investigation. Within
the CNS, patients had significantly fewer hyperintense lesions on
T2 images and gadolinium-enhancing lesions in the optic nerve
and reduced myelitis after MSC treatment. There were no gadolin-
ium-enhancing lesions in the brains of NMOSD patients during
the entire observation period. Thus, attenuation of inflammation
occurred both in the periphery and in the CNS of patients who
received MSC.
In conjunction with the improved visual function observed in
patients who received MSC, we recorded significant retinal nerve
fiber layer thickening, optic nerve diameter increases, and upper
cervical area enlargement. These findings suggest that MSCs exert
accelerated functional recovery and tissue restoration of the optic
nerve, brain and spinal cord. This is consistent with previous find-
ings that MSC therapy accelerates injury structure repair or pro-
tection and functional recovery in patients with multiple system
atrophy, stroke, cerebral palsy, spinal cord injuries, and progres-
sive MS [22,32–35]. Collectively, our data imply that the modula-
tion of immune responses as well as promotion of tissue recovery/
repair might contribute to the observed beneficial effects of MSC
on NMOSD patients.
We were able to harvest sufficient numbers of MSC from each
patient (patients had stopped previous immunosuppressive ther-
apy 1 month prior to the time of MSC harvest) that did not
express any aberrant cell-surface markers compared with MSC
harvested from healthy donors. This report is the first to describe
the successful isolation, ex vivo culture expansion, and intravenous
infusion of autologous MSC into patients with NMOSD. Despite
the large numbers of MSC and ex vivo expansion of these cells,
there was neither immediate nor delayed infusion-related toxicity
associated with the infusion of 1 9 108 MSC. No tumors were
found after 1 year of follow-up. Thus, our findings indicate that
this form of cell therapy is feasible in NMOSD patients with neuro-
logical disability.
Limitations of the study include small sample size and a single
arm, nonrandomized design. EDSS, designed for assessing neuro-
logical function in MS patients, does not have sufficient modalities
to assess vision and spinal cord function that are dominant signs
in NMOSD. A limitation of the pretest–posttest approach is that
changes in disease activity evident after treatment may not be
attributed exclusively to the effects of MSC. In addition, the age
range of recruited patients was 19–63 years. Deficiency in MSC
due to age as well as aberrancy of bone marrow due to ongoing
Table 2 A 2-Year follow-up on NMOSD patients after MSC infusion
Before MSC 1 year after infusion 2 years after infusion P1 P2 P3
ARR, mean (SD; range) 1.1 (0.9; 0.3–4.0) 0.3 (0.6; 0–2.0) 0.1 (0.3; 0–1.0) 0.002 <0.0001 0.894
Relapse free, n (%) 5* (33%) 12 (80%) 13 (87%) 0.025 0.008 1.000
EDSS, mean (SD; range) 4.9 (2.1; 2.5–8.5) 4.3 (2.2, 1.0–8.5) 4.0 (2.3, 1.0–8.5) 0.021 <0.0001 0.861
EDSS score change, n (%) 0.001 0.002 0.713
Decreased EDSS score 2* (13%) 7 (47%) 6 (40%)
Stable EDSS score 4* (27%) 8 (53%) 9 (60%)
Increased EDSS score 9* (60%) 0 0
Wilcoxon signed rank test (ARR, ESS); chi-square test (Relapse free, EDSS score change); *the last year before autologous mesenchymal stem cell infu-
sion; P1 = (before MSC) versus (1 year after infusion); P2 = (before MSC) versus (2 years after infusion); P3 = (1 year after infusion) versus (2 years
after infusion).
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autoimmunity, as previously observed in systemic lupus erythe-
matosus [36] and multiple myeloma [37], may impair the thera-
peutic potential of MSC. It is likely that a single infusion with the
given numbers of cells was unable to sustain long-lasting periph-
eral immune modulatory effects. In support of this notion, the
impact of MSC on B cells as well as Tfh cells lasted only for several
weeks after infusion. Consequently, titers of anti-AQP4 antibodies
returned to close to baseline levels (Figure S1). The ongoing
inflammatory and autoimmune responses in the periphery and
within the CNS are also expected to impair the potential repair
capacity of MSC, if any. Optimal frequency of MSC treatment for
NMOSD needs to explore. On the other hand, a 2-year follow-up
observation demonstrated that a decrease in ARR along with
reduced disability (Table 2) suggests the lasting effects of MSC in
the current study.
Despite these limitations, we have provided evidence that
NMOSD benefits from MSC therapy, possibly via immune modu-
lation and promotion of neurorepair mechanisms. Combination of
a powerful disease-modifying drug for NMOSD such as rituximab
with MSC adoptive therapy may create more favorable conditions
to facilitate the efficacy of MSC for treatment of NMOSD.
Therefore, our study encourages further investigations of MSC as
a monotherapy or combination therapy with disease-modifying
drugs for treatment of NMOSD.
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